Relmada Therapeutics's total assets for Q4 2025 were $94.00M, an increase of 531.90% from the previous quarter. RLMD total liabilities were $7.49M for the fiscal quarter, a 38.46% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.